Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Cerebrolysin cycle length: what human studies ran

Approved outside the USAHuman trial evidence
Short answer: there is no established Cerebrolysin cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. Austrian label: courses of 4 weeks in dementia (repeatable after 2 months), 10 to 21 days after stroke, 7 to 30 days after head trauma 1.
  2. Trials: 10 days (CASTA), 21 days (CARS), 12 weeks of infusions with assessment to 24 weeks (Alzheimer's disease) 5,6,7.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Cerebrolysin combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Cerebrolysin cycle length?
No. Human studies administered Cerebrolysin for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Cerebrolysin?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Cerebrolysin dosing reference Full research page

References

  1. Cerebrolysin parenterale Loesung, Fachinformation (summary of product characteristics), Zulassungsnummer 1-21380, EVER Neuro Pharma GmbH, Stand Maerz 2021 BASG (Austrian Federal Office for Safety in Health Care). 2021
  2. Cerebrolysin parenterale Loesung, Gebrauchsinformation (patient leaflet), EVER Neuro Pharma GmbH, Stand Maerz 2021 BASG (Austrian Federal Office for Safety in Health Care). 2021
  3. Cerebrolysin for acute ischaemic stroke Cochrane Database Syst Rev. 2023
  4. Cerebrolysin for vascular dementia Cochrane Database Syst Rev. 2019
  5. Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial Stroke. 2016
  6. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial Stroke. 2012
  7. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease Eur J Neurol. 2006
  8. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial Neurol Sci. 2020
  9. Drugs@FDA application data queried through openFDA for cerebrolysin (no matching application record returned on 23 October 2026) openFDA / Drugs@FDA. 2026
  10. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
  11. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026